NCT00489294 is a Phase 1 clinical trial of Syntropin in Growth Hormone Deficiency, sponsored by Phage Pharmaceuticals, Inc..

Who is sponsoring NCT00489294?

NCT00489294 is sponsored by Phage Pharmaceuticals, Inc..

What drugs are being tested in NCT00489294?

Interventions in NCT00489294: Syntropin.

What condition does NCT00489294 study?

NCT00489294 studies Growth Hormone Deficiency.

Is NCT00489294 still recruiting?

NCT00489294 is currently completed. Last updated 9 March 2012.

Last reviewed 2012-03-09 · How we verify

NCT00489294

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open-Label Study of the Pharmacokinetics and Pharmacodynamics of Syntropin (a Human Growth Hormone) in Growth Hormone-Suppressed Healthy Volunteers

Completed Phase 1 Last updated 9 March 2012

What this trial tests

Phase 1 trial testing Syntropin in Growth Hormone Deficiency in 20 participants. Completed in 1 June 2005.

Timeline

1 August 2004

Primary endpoint
1 June 2005

1 June 2005

Quick facts

Lead sponsor	Phage Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 August 2004
Primary completion	1 June 2005
Estimated completion	1 June 2005
Sites	1 location across United States

Drugs / interventions tested

Syntropin — full drug profile →

Conditions studied

Growth Hormone Deficiency — all drugs for Growth Hormone Deficiency →

Sponsor

Phage Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 45, any sex, with Growth Hormone Deficiency. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

pharmacokinetics

Sponsor's own description

The purpose of this study is to evaluate the pharmacokinetics of Syntropin (a human growth hormone) and to determine the serum concentration of IGF-1 after Syntropin injection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Growth Hormone Deficiency

Currently open trials in the same condition.

NCT06542809 — Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH · NA · recruiting
NCT05681299 — Effects of GH and Lirglutide on AgRP · Phase 4 · recruiting
NCT06455956 — Use of miRNAs in Growth Hormone Deficiency (GHD) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00489294 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Phage Pharmaceuticals, Inc.
Last refreshed: 9 March 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00489294.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing